The Lancet Oncology
Latest Publications

TOTAL DOCUMENTS

10168

(FIVE YEARS 1703)

H-INDEX

318

(FIVE YEARS 61)

Published By Elsevier

1470-2045

Latest Documents Most Cited Documents Contributed Authors Related Sources Related Keywords

Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(21)00718-x ◽

2022 ◽

Author(s):

Howard P Safran ◽

Kathryn Winter ◽

David H Ilson ◽

Dennis Wigle ◽

Thomas DiPetrillo ◽

...

Keyword(s):

Oesophageal Adenocarcinoma ◽

Her2 Overexpression ◽

Phase 3 ◽

Trimodality Treatment

Download Full-text

Clinical advances in PET–MRI for breast cancer

The Lancet Oncology ◽

10.1016/s1470-2045(21)00577-5 ◽

2022 ◽

Vol 23 (1) ◽

pp. e32-e43

Author(s):

Amy M Fowler ◽

Roberta M Strigel

Keyword(s):

Breast Cancer ◽

Clinical Advances

Download Full-text

Should brachytherapy be added to external beam radiotherapy for prostate cancer?

The Lancet Oncology ◽

10.1016/s1470-2045(21)00406-x ◽

2022 ◽

Vol 23 (1) ◽

pp. 23-25

Author(s):

Alfonso Gomez-Iturriaga ◽

Mira Keyes ◽

Jarad Martin ◽

Daniel E Spratt

Keyword(s):

Prostate Cancer ◽

External Beam Radiotherapy ◽

Download Full-text

Is non-invasive Cytosponge the holy grail for Barrett's neoplasia?

The Lancet Oncology ◽

10.1016/s1470-2045(21)00755-5 ◽

2022 ◽

Author(s):

Michael Vieth ◽

Markus F Neurath

Keyword(s):

Download Full-text

Overcoming immunotherapy resistance in NSCLC

The Lancet Oncology ◽

10.1016/s1470-2045(21)00711-7 ◽

2022 ◽

Author(s):

Michael MacManus ◽

Fiona Hegi-Johnson

Download Full-text

Use of a Cytosponge biomarker panel to prioritise endoscopic Barrett's oesophagus surveillance: a cross-sectional study followed by a real-world prospective pilot

The Lancet Oncology ◽

10.1016/s1470-2045(21)00667-7 ◽

2022 ◽

Author(s):

Nastazja Dagny Pilonis ◽

Sarah Killcoyne ◽

W Keith Tan ◽

Maria O'Donovan ◽

Shalini Malhotra ◽

...

Keyword(s):

Cross Sectional Study ◽

Barrett’S Oesophagus ◽

Sectional Study ◽

Cross Sectional ◽

Barrett's Oesophagus ◽

Biomarker Panel

Download Full-text

Prioritising access to cancer drugs

The Lancet Oncology ◽

10.1016/s1470-2045(21)00641-0 ◽

2022 ◽

Vol 23 (1) ◽

pp. e1

Author(s):

Mitchell J Elliott ◽

Eitan Amir ◽

Sallie-Anne Pearson ◽

Michael B Barton ◽

Brooke E Wilson

Keyword(s):

Download Full-text

Radiographic progression-free survival in the ACIS trial for prostate cancer

The Lancet Oncology ◽

10.1016/s1470-2045(21)00719-1 ◽

2022 ◽

Vol 23 (1) ◽

pp. e4

Author(s):

Ian F Tannock ◽

Christopher M Booth ◽

Bishal Gyawali ◽

Anthony M Joshua

Keyword(s):

Prostate Cancer ◽

Radiographic Progression ◽

Progression Free Survival ◽

Download Full-text

Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(21)00693-8 ◽

2022 ◽

Author(s):

David Cella ◽

Robert J Motzer ◽

Cristina Suarez ◽

Steven I Blum ◽

Flavia Ejzykowicz ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Patient Reported Outcomes ◽

Advanced Renal Cell Carcinoma ◽

Phase 3 ◽

Patient Reported

Download Full-text

Correction to Lancet Oncol 2021; 22: 1518–29

The Lancet Oncology ◽

10.1016/s1470-2045(21)00700-2 ◽

2022 ◽

Vol 23 (1) ◽

pp. e16

Download Full-text